Ascendis Pharma director HOLTUG LARS plans to sell 236 ordinary shares worth approximately $62,334.59. For investors, the stated purpose is to cover income tax, while the transaction record identifies the securities as compensation-linked holdings in a share plan account.
Key Highlights
- The transaction uses an indicative Market Price of 264.1296.
- The ordinary shares are held through a share plan account.
- The securities are identified as compensation-related holdings.
Ascendis Pharma A/S (NASDAQ: ASND) director HOLTUG LARS filed a Form 144 to sell 236 ordinary shares valued at approximately $62,334.59. The filing lists 09/02/2026 and states that the sale is to cover income tax.
Share Plan Account and Compensation Classification
The transaction record classifies the holdings as compensation. Citigroup Global Markets is listed with an address at 390 Greenwich St, New York, NY 10,013. The indicative market price used in the record is 264.1296. The Acquisition dates for the securities are described as various. The sale concerns HOLTUG LARS, who is identified as a director of Ascendis Pharma A/S. The transaction record identifies the shares as compensation.
FAQs
Q: What did HOLTUG LARS report in the filing?
A: HOLTUG LARS filed a Form 144 covering the proposed sale of 236 Ascendis Pharma A/S ordinary shares. The filing values the shares at approximately $62,334.59.
Q: What purpose does the filing state for the share sale?
A: The filing states that the sale of shares is to cover income tax. It also identifies the securities as compensation and lists various acquisition dates.
Q: What price and account details appear in the record?
A: The record uses an indicative market price of 264.1296 and identifies a share plan account. Citigroup Global Markets is listed with the New York address provided in the filing.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.